- 44% of Homeowners With a Mortgage Can't Sell: Zillow
- Tim Cook Should Tell Congress to Kiss His Ass
- Biotech Stock Mailbag: Amarin, MannKind, Palatin
- Millennials Won't Be Debt Free Until They Die
- What You Wear to the Office Still Matters
Protesters March Against Monsanto in More Than 250 Cities
"March Against Monsanto" protesters say they want to call attention to the dangers posed by genetically modified food.
05/25/13 - 06:29 PM EDT
Biotech Stock Mailbag: Amarin, MannKind, Palatin
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
05/24/13 - 07:00 AM EDT
Rockwell Medical Run-Up Trade Follows Financing
One trader believes Rockwell shares will rise into clinical trial results expected in July.
05/21/13 - 08:00 AM EDT
Why Keryx is Lagging But Acadia is Zooming (Hint: It's About NCE)
Two charts show how investors feel differently about Keryx and Acadia Pharma.
05/21/13 - 10:38 AM EDT
The Deal: Actavis Plays Hunter in $8.5 Billion Deal for Ireland's Warner Chilcott
Actavis took the offensive in plans to acquire specialty pharmaceuticals firm Warner Chilcott plc for $8.5 billion in stock and assumed debt.
05/20/13 - 10:01 AM EDT
Ireland Welcomes Watson Pharmaceuticals, an American Success
Another entrepreneurial U.S. startup bites the dust... sort of.
05/20/13 - 02:27 PM EDT
Video
Biotech's Next Big Thing -- ASCO II
TheStreet senior columnist Adam Feuerstein discusses the winners and losers from the research abstracts ahead of the ASCO cancer conference.
05/16/13 - 02:09 PM EDT
The 5 Dumbest Things on Wall Street This Week: May 17
Dan Loeb gets soft, Bloomberg and traders are 'Spy vs. Spy,' and Wal-Mart torpedos a cooperative reform effort by choosing its own, awkward path.
05/17/13 - 07:00 AM EDT
10 ASCO '13 Abstracts You Can Read Right Now
Get a head start on searching through ASCO abstracts with these 10 summaries.
05/15/13 - 06:00 PM EDT
Aveo Screwed Up but Its Kidney Cancer Drug Is Real
At some point, investors will give Aveo credit for tivozanib, says David Sobek.
05/15/13 - 09:24 AM EDT
Synta Is Run-Up to ASCO Lung Cancer Data
The market overreacted to the resignation of Synta's R&D chief.
05/14/13 - 10:16 AM EDT
Cullen/Frost Has Earned Its Premium, and More
The stock has the highest forward P/E among components of the KBW Bank Index, justified by strong long-term earnings and growth prospects.
05/14/13 - 10:23 AM EDT
